NEU Stock Overview
A biopharmaceutical company, develops drugs for the treatment of neurological disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for NEU from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Neuren Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$12.58 |
| 52 Week High | AU$24.00 |
| 52 Week Low | AU$10.90 |
| Beta | 2.08 |
| 1 Month Change | -5.13% |
| 3 Month Change | 3.28% |
| 1 Year Change | -37.69% |
| 3 Year Change | 209.09% |
| 5 Year Change | 1,158.00% |
| Change since IPO | 413.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| NEU | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 7.4% | 5.3% | 1.8% |
| 1Y | -37.7% | -12.7% | 0.1% |
Return vs Industry: NEU underperformed the Australian Pharmaceuticals industry which returned -12.7% over the past year.
Return vs Market: NEU underperformed the Australian Market which returned 0.1% over the past year.
Price Volatility
| NEU volatility | |
|---|---|
| NEU Average Weekly Movement | 8.0% |
| Pharmaceuticals Industry Average Movement | 10.7% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in AU Market | 15.6% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: NEU has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: NEU's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Jon Pilcher | www.neurenpharma.com |
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes.
Neuren Pharmaceuticals Limited Fundamentals Summary
| NEU fundamental statistics | |
|---|---|
| Market cap | AU$1.59b |
| Earnings (TTM) | AU$142.04m |
| Revenue (TTM) | AU$216.83m |
11.2x
P/E Ratio7.4x
P/S RatioIs NEU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NEU income statement (TTM) | |
|---|---|
| Revenue | AU$216.83m |
| Cost of Revenue | AU$32.97m |
| Gross Profit | AU$183.86m |
| Other Expenses | AU$41.82m |
| Earnings | AU$142.04m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.12 |
| Gross Margin | 84.79% |
| Net Profit Margin | 65.51% |
| Debt/Equity Ratio | 0% |
How did NEU perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 12:37 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neuren Pharmaceuticals Limited is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Russell Wright | Barclay Pearce Capital Pty Limited |
| Melissa Benson | Barrenjoey Markets Pty Limited |
| Thomas Wakim | Bell Potter |